Gauss Engineering Solutions’ Post

Join me at the Northland Capital Markets Virtual Growth Conference for an overview of IceCure Medical and a review of our latest developments and catalysts.

The 42nd VICENZA COURSE on AKI, CRRT & ECOS is approaching! (Vicenza, June 11-13)   Don’t miss the Meet the Expert session “Polymyxin B Hemoadsorption in Endotoxic Septic Shock: What We Learned till Now from Asia, Europe and US Clinical Experiences”. Save the Date: Tuesday, June 11 | 18.00 – 18.30 #Endotoxemia #EndotoxicShock #SAAKI #PolymyxinBAdsorption #PatientFirst

AAGL 2024, 53rd Global Congress on MIGS. Tune into the Rythm of Innovation. Enhance your surgical expertise, network with leaders, and enojoy the soulful sounds of the big easy. Register today by clicking the link below. https://lnkd.in/dbYF3t_w #AAGL2024 #ISFGS #AAGL #fluorescence #ICG #FGS #MIGS #fluorescenceimaging Joao Paulo Epprecht

🎉 As someone who worked on developing this trial in its early stages, this news is incredible! 🚀 Janssen Pharmaceuticals has received a positive CHMP (Committee for Medicinal Products for Human Use) opinion for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) in the treatment of earlier lines of relapsed and refractory multiple myeloma (RRMM). This groundbreaking recommendation follows results from the Phase 3 CARTITUDE-4 study, demonstrating cilta-cel's potential to offer significant benefits to patients in earlier stages of treatment. 🔍 Key Highlights: Advancing Treatment: Cilta-cel has shown superiority over daily oral therapies, providing a promising option for patients facing adherence challenges. Milestone Achievement: This recommendation marks a significant milestone in the treatment of multiple myeloma, offering new hope to patients at earlier stages of the disease. Future Outlook: Janssen remains committed to advancing cilta-cel and other immunotherapies, aiming to redefine the treatment paradigm and ultimately deliver improved outcomes for patients. This positive development underscores Janssen's dedication to innovation and its mission to make disease a thing of the past. Stay tuned for more updates as we continue to push the boundaries of medical science! #MedicalBreakthrough #CancerTreatment #JanssenInnovation

Looking forward to lots of intriguing discussions! Let me or Dr. Christina Deschermeier know if you're going to be at ECCMID and would like us to save you a time slot for a detailed chat, or pop by out booth E8.2. See you there! 😁 #ntds #elisa #diagnostics

Landmark RCT - pronounces further, the clinical relevance of intermediate sizes on Effective Orifice Area.

𝐖𝐞’𝐫𝐞 𝐚𝐭𝐭𝐞𝐧𝐝𝐢𝐧𝐠 𝐭𝐡𝐞 𝐄𝐌𝐀’𝐬 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦 𝐨𝐧 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐚𝐥 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐬 (𝐀𝐓𝐌𝐏𝐬) 💊   It’s a busy time for conferences and events, and we’re excited to share that Wim Neckebroeck and Domien Verdonck will be attending the EMA’s Scientific Symposium on ATMPs. The session takes place on 10 October under the theme of ‘Contribution, evolution, revolution’.   This symposium will showcase how the work of the Committee for Advanced Therapies (CAT) has contributed to the regulatory framework for ATMPs in Europe and to the approval of innovative products. It will also outline the evolution of CAT and its adaptation to the challenges posed by novel classes of ATMPs.    The ultimate objective is to ensure that high quality, safe and efficacious products become new treatment options. Many more novel developments are on the horizon. Each has the possibility to revolutionise patient care, and their own merits and challenges. Speakers and audience will discuss the vision for ATMPs for the next 15 years.   Wim and Domien are looking forward to insightful discussions and networking with peers.   #EMA #ATMPs

We are on the final countdown to #WorldADC London! Addressing the current state of the ADC landscape and asking what we expect to see progressing through the clinic next, is our Account Lead, Jake Morris. Full details of the talk are: 📈 The total number of ADC programs has increased massively over the last few years, what are the emerging trends from this recent influx of activity? 🔬 From Payloads & Linkers to Targets & Bispecifics, which approaches are seeing the most use in each stage of development? 💊 What were the key highlights and updates for ADC development across 2023? Download the full event guide today to get full details of the 4-day agenda, including our Pre-Conference Seminar Day ADC combination in clinical trials presentation. 👇 https://lnkd.in/ePtRPBYq Catch our ADC team, Jia, Jake, Raj, and Eleni, in the exhibition hall at booth #34 and grab some goodies too! #WorldADC #WADC #drugdevelopment #ADClandscape #payloads #targets #bispecifics #ADCcombination #clinicaltrials

It's been nearly two years since we held the last Advanced Lateral Flow Conference. At the end of 2022 the lateral flow industry was riding a wave of exuberance following the expansion driven by Covid testing requirements. But even then we saw a time of contraction and difficulty coming and some of the key topics of that conference focused on the pain that was likely to come and methods for reallocating the newly built infrastructure for other diagnostic initiatives to ease that pain. The anticipated trough came in the 2022-2023 timeframe, with industry-wide layoffs and mothballing of infrastructure. Coupled with the higher cost of investment due to macroeconomic factors and the restriction of available capital for startups and even internal programs at larger diagnostics companies, the number of new product launches remained low through 2023. As 2024 progresses, it is now anticipated that we may be at the start of the upswing, as more capital becomes available, M&A activity increases, and the number of new product development programs rises. This year's ALFC, to be held in San Diego on February 13th and 14th will discuss some of the key issues around funding, innovation and the practicalities of development and manufacturing of lateral flow products in the current and anticipated future industry environment. There will be presentations on topics linked funding, to the opportunity presented by AI in point of care diagnostics, as well as industry panels discussing topics such as integration of digital technology with at-home testing systems. Coupled with the usual networking opportunities and exposure to all of the key industry suppliers and service providers, the ALFC is a unique opportunity for developers, manufacturers and those seeking to understand the lateral flow and point of care space. There are still some attendee and sponsor spaces available. Check out https://lnkd.in/gxU9x4jX . See you in San Diego! #ALFC2024 #Diagnostics #Conference #AssayDevelopment

“We're too small for a CRO partnership, aren’t we?" "Our CRO partner relationship is mixed at best.” "The partnership with our CRO is great!” What’s your take? Join peers to discuss the clinical outsourcing trends and strategies that work for you. Our goal is to help you accelerate growth and navigate this complex landscape, and the forum’s roundtable format provides an environment that promotes collaboration and an open exchange of ideas. We'd love to see you there! TriRadial Navigation Forum 2024 - Cambridge, MA Tuesday, October 22 Roundtable, 2-5pm EST Happy Hour, 5-6pm EST Register now to connect with industry leaders and gain the insights you need to chart your course with confidence. https://lnkd.in/gPx7TvQ4 #TriRadial #biopharma #lifesciences #biotech #consulting #growth #clinicaloutsourcing #clinicaltrials #CROselection #NavigationForum #NavigatingGrowth #digitalhealth #technology #innovation #quality #performance #clinicalresearch #clinicaldatamanagement #clinicalstudies #clinicaloperations #clinicaloutcomes #clinicaloperations #clinicaldevelopment #pharmaceuticals #outsourcing #thirdpartyvendors